miRNA Plasmid Composition for Serotonin Receptor Silencing

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Dysregulation of bioactive molecules, such as serotonin receptors, leads to homeostatic imbalance and associated diseases, necessitating therapies to regulate their expression.

Innovation Solution

Compositions comprising recombinant plasmids that encode for micro-interfering ribonucleic acid (miRNA) sequences are administered to upregulate miRNA production, targeting and degrading or inactivating the mRNA of specific serotonin receptors, thereby reducing their bioavailability.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If serotonin receptor expression is increased to enhance neurotransmission, then neurotransmission efficiency is improved, but homeostatic imbalance and disease occur

Engineering Contradiction:
Improveneurotransmission efficiencyVSAvoidhomeostatic balance
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent employs endogenous miRNA molecules that naturally regulate serotonin receptor expression through feedback mechanisms. When serotonin receptor levels become excessive, the miRNA molecules bind to complementary mRNA sequences and inhibit translation or promote degradation, thereby reducing receptor production and restoring homeostatic balance.

Inventive Principle:
Principle #23Feedback

Solution Approach 2:

The invention modulates the expression level of serotonin receptors by introducing recombinant plasmids that encode miRNA molecules. These plasmids change the parameter of receptor concentration in a controlled manner, allowing dynamic adjustment between neurotransmission efficiency and homeostatic balance based on physiological needs.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If miRNA production is upregulated to decrease serotonin receptor bioavailability, then disease treatment is achieved, but gene expression regulation complexity increases

Engineering Contradiction:
Improvedisease treatment efficacyVSAvoidgene expression regulation system
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent uses recombinant plasmids as intermediary vehicles to deliver miRNA coding sequences into target cells. These plasmids serve as mediators that convert external therapeutic intent into internal gene expression changes, simplifying the overall treatment approach while achieving precise regulation of serotonin receptor levels.

Inventive Principle:
Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The compositions effectively decrease the production and bioavailability of serotonin receptors, potentially ameliorating diseases resulting from their dysregulation by enhancing endogenous miRNA production and silencing the target mRNA.

Implementation Method 1

The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated

Methodology Applied
Scientific EffectComplementary base pairing:

Data Source

PatentUS12565657B2Composition for regulating production of interfering ribonucleic acid
Publication Date: 2026.03.03 WYVERN PHARMACEUTICALS INC

AI summary

Some embodiments of the present disclosure relate to one or more compositions that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complementary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule and the miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA, thereby decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions. In some embodiments of the present disclosure, the target biomolecule is a serotonin receptor, such as serotonin receptor 5HT1a, 5HT1b, 5HT1d, 5HT1e, 5HT1f, 5HT2a, 5HT2b, 5HT2c, 5HT3, 5HT4, 5HT6, or 5HT7.